Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... MD (PRWEB) May 23, 2013 Can ... off from work motivate members of the public to ... researchers including Johns Hopkins Carey Business School ... emphatic yes. Pointing to a large body of recent ... in the May 24, 2013, issue of Science that ...
(Date:5/23/2013)... May 23, 2013 The maker community ... types of inventions. They focus on learning practical skills ... community gravitate toward bringing their ideas to life via ... Movement, works on making projects using biology. Glowing Plant ... plants to make them glow with bioluminescence genes, and ...
(Date:5/23/2013)... Pa. , May 23, 2013 ... research and advisory firms for specialized biopharmaceutical issues, ... hepatologists, and infectious disease specialists reported that in ... patients (e.g., intentionally delaying treatment) in anticipation of ... than six months ago, when only 6 percent ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... Applications International Corporation (SAIC) (NYSE: SAI ) ... chief executive officer of SAIC-Frederick, Inc., a wholly owned ... Dr. Larry Arthur, who has served as CEO since ... SAIC-Frederick provides operations and technical support to ...
... CAMBRIDGE, Mass., May 24, 2011 Radius Health, Inc. ... $91 million in its third financing round, including $66 ... Capital, Healthcare Financial Services and Oxford Finance LLC to ... investors, including BB Biotech AG, Brookside Capital, Saints Capital, ...
... WASHINGTON, May 23, 2011The Annual Meeting of the American ... June 2, 2011, in New Orleans, Louisiana. Crystallography is ... in regular crystalline solids and in complicated molecules. The ... the structure of important materials are often calculated by ...
Cached Biology Technology:Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc. 2Dr. David Heimbrook Appointed Chief Executive Officer of SAIC-Frederick, Inc. 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 2Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 4Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 2Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 3Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 4
(Date:5/23/2013)... to be the world,s most popular fruit, can be ... with purple GM varieties. , "Working with GM ... the addition of a specific compound, allows us to ... Professor Cathie Martin from the John Innes Centre. , ... better flavour, health and shelf life characteristics because even ...
(Date:5/23/2013)... School of Public Health at Emory University, along ... have received a $4 million grant over four ... University (Health and Exposome Research Center: Understanding Lifetime ... grant awarded in the United States. , ... Institute of Environmental Health Sciences (NIEHS) of the ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
... into the forest, they left a trail of breadcrumbs ... phones, Global Positioning System (GPS), WiFi, and Bluetooth are ... and colleagues while helping us find our location and ... such devices, with few exceptions, today,s firefighters still rely ...
... "happy blue baby" because of her bluish skin color ... history when one of her physicians discovered something new ... have identified hundreds of mutations in genes that carry ... in everyone,s red blood cells. By tradition, whoever discovers ...
... which can cause wide-spread disease and may be resistant ... their weaknesses. A team of Canadian scientists discovered that ... mixtures can significantly boost the effectiveness of those agents ... online in The FASEB Journal ( http://www.fasebj.org ...
Cached Biology News:Wireless 'breadcrumbs' that won’t become toast when baked...or soggy when hosed 2Wireless 'breadcrumbs' that won’t become toast when baked...or soggy when hosed 3Hematologist discovers, names the 'Toms River' blood mutation in N.J. family 2Scientists develop a fatty 'kryptonite' to defeat multidrug-resistant 'Super bugs' 2
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: